These new guidelines contain wide-ranging recommendations on the use of beta-blockers, sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1, and other medical therapies to treat chronic coronary disease. They also contain recommendations on how to evaluate, diagnose, and risk stratify patients, as well as the role of coronary revascularization when medical therapy does not work.
Visit this article from tctMD for a summary of the guidelines, including additional observations from the authors.Visit this article from tctMD for a summary of the guidelines, including additional observations from the authors.
You are here:
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Submitted by: Cameron Lind
Source: Circulation
Keywords:
Author(s): Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, Vera Bittner, LaPrincess C. Brewer, Susan Halli Demeter, Dave L. Dixon, William F. Fearon, Beverly Hess, Heather M. Johnson, Dhruv S. Kazi, Dhaval Kolte, Dharam J. Kumbhani, Jim LoFaso, Dhruv Mahtta, Daniel B. Mark, Margo Minissian, Ann Marie Navar, Amit R. Patel, Mariann R. Piano, Fatima Rodriguez, Amy W. Talbot, Viviany R. Taqueti, Randal J. Thomas, Sean van Diepen, Barbara Wiggins and Marlene S. Williams
